var data={"title":"Pharmacotherapy and psychosocial interventions for schizophrenia in children and adolescents","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pharmacotherapy and psychosocial interventions for schizophrenia in children and adolescents</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/contributors\" class=\"contributor contributor_credentials\">Brian Skehan, MD, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/contributors\" class=\"contributor contributor_credentials\">Yael Dvir, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/contributors\" class=\"contributor contributor_credentials\">Jean Frazier, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/contributors\" class=\"contributor contributor_credentials\">David Brent, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/contributors\" class=\"contributor contributor_credentials\">Stephen Marder, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/contributors\" class=\"contributor contributor_credentials\">Richard Hermann, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Mar 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 08, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H3346353019\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Schizophrenia in children and adolescents is a syndrome consisting of positive and negative symptoms of psychosis that impact development and cognitive functioning. The etiology of this syndrome is poorly understood, but early diagnosis and treatment are critical to limit the morbidity of the disorder.</p><p>Childhood-onset schizophrenia usually represents a more severe form of the disorder with more prominent prepsychotic developmental disorders, structural brain abnormalities, and genetic risk factors [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/1-4\" class=\"abstract_t\">1-4</a>]. </p><p>This topic reviews pharmacotherapy and psychosocial interventions for schizophrenia in children and adolescents. The epidemiology, pathogenesis, clinical manifestations, course, assessment, diagnosis of schizophrenia in children are reviewed separately. The epidemiology, pathogenesis, clinical manifestations, course, assessment, diagnosis, and treatment of schizophrenia in adults (including long-acting injectable antipsychotics, <a href=\"topic.htm?path=clozapine-pediatric-drug-information\" class=\"drug drug_pediatric\">clozapine</a>, and medication to treat side effects) are also reviewed separately. The evaluation and management of treatment-resistant schizophrenia are also reviewed separately. (See <a href=\"topic.htm?path=schizophrenia-in-children-and-adolescents-epidemiology-pathogenesis-clinical-manifestations-course-assessment-and-diagnosis\" class=\"medical medical_review\">&quot;Schizophrenia in children and adolescents: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis&quot;</a> and <a href=\"topic.htm?path=schizophrenia-in-adults-epidemiology-and-pathogenesis\" class=\"medical medical_review\">&quot;Schizophrenia in adults: Epidemiology and pathogenesis&quot;</a> and <a href=\"topic.htm?path=schizophrenia-in-adults-clinical-manifestations-course-assessment-and-diagnosis\" class=\"medical medical_review\">&quot;Schizophrenia in adults: Clinical manifestations, course, assessment, and diagnosis&quot;</a> and <a href=\"topic.htm?path=pharmacotherapy-for-schizophrenia-acute-and-maintenance-phase-treatment\" class=\"medical medical_review\">&quot;Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment&quot;</a> and <a href=\"topic.htm?path=pharmacotherapy-for-schizophrenia-long-acting-injectable-antipsychotic-drugs\" class=\"medical medical_review\">&quot;Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs&quot;</a> and <a href=\"topic.htm?path=pharmacotherapy-for-schizophrenia-side-effect-management\" class=\"medical medical_review\">&quot;Pharmacotherapy for schizophrenia: Side effect management&quot;</a> and <a href=\"topic.htm?path=psychosocial-interventions-for-schizophrenia\" class=\"medical medical_review\">&quot;Psychosocial interventions for schizophrenia&quot;</a> and <a href=\"topic.htm?path=evaluation-and-management-of-treatment-resistant-schizophrenia\" class=\"medical medical_review\">&quot;Evaluation and management of treatment-resistant schizophrenia&quot;</a> and <a href=\"topic.htm?path=guidelines-for-prescribing-clozapine-in-schizophrenia\" class=\"medical medical_review\">&quot;Guidelines for prescribing clozapine in schizophrenia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1604998047\"><span class=\"h1\">APPROACH TO TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Our approach to treating schizophrenia in children and adolescents is described separately. (See <a href=\"topic.htm?path=approach-to-treating-schizophrenia-in-children-and-adolescents\" class=\"medical medical_review\">&quot;Approach to treating schizophrenia in children and adolescents&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H118040686\"><span class=\"h1\">ANTIPSYCHOTIC MEDICATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antipsychotic medication is the cornerstone of treatment for schizophrenia in youth, augmented by psychosocial treatment. Antipsychotics are most commonly taken orally in daily divided doses. Selection among antipsychotics and dosing (<a href=\"image.htm?imageKey=PSYCH%2F116251\" class=\"graphic graphic_table graphicRef116251 \">table 1</a>) in the pediatric population is reviewed separately. (See <a href=\"topic.htm?path=approach-to-treating-schizophrenia-in-children-and-adolescents\" class=\"medical medical_review\">&quot;Approach to treating schizophrenia in children and adolescents&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H753168222\"><span class=\"h2\">Efficacy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Randomized clinical trials have shown several second-generation antipsychotics (with the exception of <a href=\"topic.htm?path=ziprasidone-pediatric-drug-information\" class=\"drug drug_pediatric\">ziprasidone</a> [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/5\" class=\"abstract_t\">5</a>]) to reduce positive and negative symptoms of schizophrenia in youth in comparison with placebo: &#160; </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=olanzapine-pediatric-drug-information\" class=\"drug drug_pediatric\">Olanzapine</a> [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/6\" class=\"abstract_t\">6</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information\" class=\"drug drug_pediatric\">Aripiprazole</a> [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/7-9\" class=\"abstract_t\">7-9</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=quetiapine-pediatric-drug-information\" class=\"drug drug_pediatric\">Quetiapine</a> [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/10\" class=\"abstract_t\">10</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=risperidone-pediatric-drug-information\" class=\"drug drug_pediatric\">Risperidone</a> [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/11\" class=\"abstract_t\">11</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=lurasidone-drug-information\" class=\"drug drug_general\">Lurasidone</a> [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/12\" class=\"abstract_t\">12</a>]</p><p/><p>As an example, a 2017 clinical trial randomly assigned 146 patients age 13 to 17 with schizophrenia to receive either <a href=\"topic.htm?path=aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information\" class=\"drug drug_pediatric\">aripiprazole</a> or placebo for a 52-week maintenance period [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/9\" class=\"abstract_t\">9</a>]. Over the course of the study, patients assigned to receive aripiprazole experienced a longer mean time to exacerbation of psychotic <span class=\"nowrap\">symptoms/impending</span> relapse compared with placebo (hazard ratio = 0.46, 95% CI 0.24-0.88). Aripiprazole had lower rates of treatment-emergent adverse events compared with placebo (3.1 versus 12.5 percent). Rates of weight gain, extrapyramidal symptoms, and somnolence in the aripiprazole group were similar or lower compared with the placebo group. &#160;</p><p>In addition, comparative clinical trials in youth with schizophrenia have shown greater efficacy for <a href=\"topic.htm?path=paliperidone-pediatric-drug-information\" class=\"drug drug_pediatric\">paliperidone</a> in comparison to <a href=\"topic.htm?path=aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information\" class=\"drug drug_pediatric\">aripiprazole</a> [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/13,14\" class=\"abstract_t\">13,14</a>], and for <a href=\"topic.htm?path=clozapine-pediatric-drug-information\" class=\"drug drug_pediatric\">clozapine</a> in comparison to <a href=\"topic.htm?path=haloperidol-pediatric-drug-information\" class=\"drug drug_pediatric\">haloperidol</a> and <a href=\"topic.htm?path=olanzapine-pediatric-drug-information\" class=\"drug drug_pediatric\">olanzapine</a> [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/15,16\" class=\"abstract_t\">15,16</a>]. Due to its more severe side effect profile compared with other antipsychotics, clozapine&rsquo;s use is generally restricted to patients who fail to respond to other antipsychotics; its efficacy is reviewed in further detail below. (See <a href=\"#H3756837637\" class=\"local\">'Clozapine'</a> below.)</p><p>Few first-generation antipsychotics currently in clinical use have directly been shown to be efficacious for symptoms of schizophrenia in youth. Those that have been shown to be efficacious in clinical trials are listed below:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=chlorpromazine-pediatric-drug-information\" class=\"drug drug_pediatric\">Chlorpromazine</a> [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/17\" class=\"abstract_t\">17</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=loxapine-drug-information\" class=\"drug drug_general\">Loxapine</a> [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/18\" class=\"abstract_t\">18</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=haloperidol-pediatric-drug-information\" class=\"drug drug_pediatric\">Haloperidol</a> [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/18,19\" class=\"abstract_t\">18,19</a>]</p><p/><p><a href=\"topic.htm?path=perphenazine-pediatric-drug-information\" class=\"drug drug_pediatric\">Perphenazine</a>, while not tested in clinical trials of youths with schizophrenia, is also used in this population based on our and other clinicians&rsquo; experience in youth as well as results from efficacy studies in adults. </p><p class=\"headingAnchor\" id=\"H3756837637\"><span class=\"h3\">Clozapine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=clozapine-pediatric-drug-information\" class=\"drug drug_pediatric\">Clozapine</a> has demonstrated superior efficacy for treatment-resistant schizophrenia in three randomized clinical trials in youth in comparison with <a href=\"topic.htm?path=haloperidol-pediatric-drug-information\" class=\"drug drug_pediatric\">haloperidol</a> [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/15\" class=\"abstract_t\">15</a>], <a href=\"topic.htm?path=olanzapine-pediatric-drug-information\" class=\"drug drug_pediatric\">olanzapine</a> [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/16\" class=\"abstract_t\">16</a>], and high-dose olanzapine [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/20\" class=\"abstract_t\">20</a>]. As an example, a trial of 39 youth found that the group randomly assigned to receive clozapine had a higher rate of response (ie, a decrease of 30 percent or more on the Brief Psychiatric Rating Scale) compared with high dose olanzapine (66 versus 33 percent) [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/20\" class=\"abstract_t\">20</a>]. These trials enrolled patients as young as seven [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/15,16\" class=\"abstract_t\">15,16</a>]. </p><p>Due to its more severe side effect profile, the use of <a href=\"topic.htm?path=clozapine-pediatric-drug-information\" class=\"drug drug_pediatric\">clozapine</a> is generally restricted to patients that have not responded to other antipsychotics. (See <a href=\"#H1502854672\" class=\"local\">'Clozapine'</a> below and <a href=\"topic.htm?path=approach-to-treating-schizophrenia-in-children-and-adolescents#H4107434002\" class=\"medical medical_review\">&quot;Approach to treating schizophrenia in children and adolescents&quot;, section on 'Treatment resistant'</a>.)</p><p>Guidelines for prescribing <a href=\"topic.htm?path=clozapine-pediatric-drug-information\" class=\"drug drug_pediatric\">clozapine</a>, including information about pretreatment assessment, administration, treatment <span class=\"nowrap\">monitoring/reporting,</span> and adverse effects in adults, are reviewed separately. (See <a href=\"topic.htm?path=guidelines-for-prescribing-clozapine-in-schizophrenia\" class=\"medical medical_review\">&quot;Guidelines for prescribing clozapine in schizophrenia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H477881056\"><span class=\"h3\">Long-acting injectable formulations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although less commonly used in youth than in adults, long-acting injectable (LAI) antipsychotics are used in patients with schizophrenia who have difficultly adhering to daily oral dosing. There has been little rigorous testing of LAI antipsychotics in this population, though published research supports the safety and efficacy of the formulation: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A randomized clinical trial in 113 adolescents (ages 12 to 17 years) with schizophrenia randomly assigned to <a href=\"topic.htm?path=paliperidone-pediatric-drug-information\" class=\"drug drug_pediatric\">paliperidone</a> extended release or oral <a href=\"topic.htm?path=aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information\" class=\"drug drug_pediatric\">aripiprazole</a> for eight weeks [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/13\" class=\"abstract_t\">13</a>]. Both groups improved over the course of the trial; no difference was seen in response rates between the two drugs (67.9 versus 76.3 percent). Risk of extrapyramidal symptoms was slightly higher in paliperidone extended release over aripiprazole. &#160; </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Open trials and case reports have described the use of LAI antipsychotics in 36 children (mean age of 12 years) with bipolar or schizophrenia spectrum disorders [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/21\" class=\"abstract_t\">21</a>]. Twenty-four subjects received LAI <a href=\"topic.htm?path=risperidone-pediatric-drug-information\" class=\"drug drug_pediatric\">risperidone</a> and eight received <a href=\"topic.htm?path=paliperidone-pediatric-drug-information\" class=\"drug drug_pediatric\">paliperidone</a> palmitate. <a href=\"topic.htm?path=fluphenazine-drug-information\" class=\"drug drug_general\">Fluphenazine</a> decanoate, <a href=\"topic.htm?path=aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information\" class=\"drug drug_pediatric\">aripiprazole</a> extended-release injectable, <a href=\"topic.htm?path=zuclopenthixol-united-states-not-available-drug-information\" class=\"drug drug_general\">zuclopenthixol</a> decanoate, and <a href=\"topic.htm?path=olanzapine-pediatric-drug-information\" class=\"drug drug_pediatric\">olanzapine</a> extended release were each used in one patient case reports. Most cases reported clinical improvement and the majority of individuals were reported to tolerate the medication well.</p><p/><p>Optimal dosing of LAI antipsychotics for pediatric schizophrenia is not known. In our clinical experience, older adolescents (16 years and older) are treated with LAI antipsychotics using adult dosing with results similar to those seen in adults (<a href=\"image.htm?imageKey=PSYCH%2F59201\" class=\"graphic graphic_table graphicRef59201 \">table 2</a>).</p><p>Treatment of schizophrenia in adults with LAI antipsychotics is reviewed separately. (See <a href=\"topic.htm?path=pharmacotherapy-for-schizophrenia-long-acting-injectable-antipsychotic-drugs\" class=\"medical medical_review\">&quot;Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2178695808\"><span class=\"h2\">Side effects</span></p><p class=\"headingAnchor\" id=\"H750318012\"><span class=\"h3\">First-generation antipsychotics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Common adverse effects of first-generation antipsychotics include extrapyramidal side effects (tremor, bradykinesia, shuffling gait, akathisia), acute dystonic reactions, tardive dyskinesia, and hyperprolactinemia. First-generation antipsychotic use in adults is reviewed separately. (See <a href=\"topic.htm?path=first-generation-antipsychotic-medications-pharmacology-administration-and-comparative-side-effects\" class=\"medical medical_review\">&quot;First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects&quot;</a>.)</p><p><a href=\"topic.htm?path=pimozide-pediatric-drug-information\" class=\"drug drug_pediatric\">Pimozide</a>, <a href=\"topic.htm?path=thioridazine-pediatric-drug-information\" class=\"drug drug_pediatric\">thioridazine</a>&nbsp;and intravenous <a href=\"topic.htm?path=haloperidol-pediatric-drug-information\" class=\"drug drug_pediatric\">haloperidol</a> prolong the QT interval, particularly at higher doses. These medications should be avoided in patients with cardiac disease, a family history of sudden death, and in conjunction with other medications that prolong the QT interval such as antiarrhythmics and <a href=\"topic.htm?path=erythromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">erythromycin</a>. </p><p class=\"headingAnchor\" id=\"H1022592751\"><span class=\"h3\">Second-generation antipsychotics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Adverse effects associated with second-generation antipsychotics include metabolic side effects (weight gain, diabetes, hyperlipidemia) QT interval prolongation, akathisia, and tardive dyskinesia. Some of these medications also cause extrapyramidal side effects but generally at rates lower than first-generation agents. Second-generation antipsychotic use in adults is reviewed separately. (See <a href=\"topic.htm?path=second-generation-antipsychotic-medications-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">&quot;Second-generation antipsychotic medications: Pharmacology, administration, and side effects&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1502854672\"><span class=\"h4\">Clozapine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>More severe adverse effects of <a href=\"topic.htm?path=clozapine-pediatric-drug-information\" class=\"drug drug_pediatric\">clozapine</a>, particularly agranulocytosis, has generally limited the medication&rsquo;s use to treatment resistant cases. (See <a href=\"topic.htm?path=approach-to-treating-schizophrenia-in-children-and-adolescents#H4107434002\" class=\"medical medical_review\">&quot;Approach to treating schizophrenia in children and adolescents&quot;, section on 'Treatment resistant'</a>.)</p><p>A 2014 systematic review of 16 trials of <a href=\"topic.htm?path=clozapine-pediatric-drug-information\" class=\"drug drug_pediatric\">clozapine</a> in youth found that sedation and hypersalivation occurred in over 90 percent of patients [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/22\" class=\"abstract_t\">22</a>]. Other common side effects were enuresis, constipation, weight gain, and nonspecific electroencephalogram changes (10 to 60 percent). </p><p>Neutropenia was seen in 6 to 15 percent of cases. Neutropenia has been found to be more frequent in clozapine-treated children and adolescents compared with adults. As an example, in an eight-month study of 172 youth (mean age, 18 years), 13 percent developed neutropenia [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/23\" class=\"abstract_t\">23</a>]; however, the cumulative risk of agranulocytosis was only 0.8 percent over the first year of treatment. Some of the risk may be mitigated by concurrent treatment with <a href=\"topic.htm?path=lithium-pediatric-drug-information\" class=\"drug drug_pediatric\">lithium</a> to raise the white blood cell count [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/24,25\" class=\"abstract_t\">24,25</a>]. </p><p>Under the Risk Evaluation&nbsp;and&nbsp;Mitigation<strong> </strong>Strategy program in the United States, the risk of agranulocytosis with <a href=\"topic.htm?path=clozapine-pediatric-drug-information\" class=\"drug drug_pediatric\">clozapine</a> is managed through regular monitoring and registry reporting of neutrophil counts (<a href=\"http://www.clozapinerems.com/&amp;token=NK91I08KOJ1eJ1hT1o/oHi8b+v1cn8WrL0zLzHrrXsluh6Unmw/J+u+UkbMb04T3&amp;TOPIC_ID=112632\" target=\"_blank\" class=\"external\">www.clozapinerems.com</a>). Clozapine is stopped in cases of moderate and severe neutropenia; the medication can be restarted in some patients [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/23,25\" class=\"abstract_t\">23,25</a>].</p><p>Children may be at greater risk for seizure when taking <a href=\"topic.htm?path=clozapine-pediatric-drug-information\" class=\"drug drug_pediatric\">clozapine</a> compared with the adult population. A baseline electroencephalogram should be completed in cases with focal deficits on neurological exam, evidence of neurodevelopmental delay, or other concern of neurological abnormalities including focal neurological deficits or neurodevelopmental delay. A repeat electroencephalogram is indicated during dose titration or treatment if there are behavioral changes that could be consistent with seizure [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/26\" class=\"abstract_t\">26</a>].</p><p>Comparative studies in youth have shown that <a href=\"topic.htm?path=clozapine-pediatric-drug-information\" class=\"drug drug_pediatric\">clozapine</a> can result in increased tachycardia or mean blood pressure compared with <a href=\"topic.htm?path=olanzapine-pediatric-drug-information\" class=\"drug drug_pediatric\">olanzapine</a> [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/16\" class=\"abstract_t\">16</a>]. Weight gain with clozapine (0.9 to 9.5 kg in a study of 97 youth) was less than olanzapine (3.8 to 16.2 kg in 353 youth) in a review of randomized, cohort, and pharmacoepidemiologic studies [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/16,27\" class=\"abstract_t\">16,27</a>]. (See <a href=\"topic.htm?path=pharmacotherapy-for-schizophrenia-side-effect-management\" class=\"medical medical_review\">&quot;Pharmacotherapy for schizophrenia: Side effect management&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H215092351\"><span class=\"h3\">Differences in youth</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children and adolescents, compared with adults, are at higher risk of many of the side effects associated with antipsychotic use, including extrapyramidal side effects, withdrawal dyskinesias, elevated prolactin, weight gain, and metabolic abnormalities [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/28-32\" class=\"abstract_t\">28-32</a>]. (See <a href=\"topic.htm?path=pharmacotherapy-for-schizophrenia-side-effect-management\" class=\"medical medical_review\">&quot;Pharmacotherapy for schizophrenia: Side effect management&quot;</a>.)</p><p>Tardive dyskinesias are less common in youth compared with adult and older-adult populations (0.4 versus 6.8 percent) [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/28-33\" class=\"abstract_t\">28-33</a>]. The risk of tardive dyskinesia in children appears to be greatest with first-generation antipsychotics with minimal or no risk seen with second-generation antipsychotics, although some of these data are extrapolated from adult studies [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/28\" class=\"abstract_t\">28</a>]. (See <a href=\"topic.htm?path=tardive-dyskinesia-etiology-and-epidemiology\" class=\"medical medical_review\">&quot;Tardive dyskinesia: Etiology and epidemiology&quot;</a> and <a href=\"topic.htm?path=tardive-dyskinesia-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Tardive dyskinesia: Clinical features and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1698346858\"><span class=\"h3\">Other adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nausea and sedation are common side effects of antipsychotic treatment in all patients but often remit over time and should not be considered reasons to terminate treatment [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/34\" class=\"abstract_t\">34</a>]. Neuroleptic malignant syndrome, agranulocytosis, myocarditis, cardiomyopathy, and severe allergic reactions are also possible with antipsychotic medications and are a reason to terminate that medication immediately and provide appropriate medical care and support. </p><p class=\"headingAnchor\" id=\"H3172361488\"><span class=\"h3\">Management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Management of side effects associated with antipsychotic medications is reviewed separately. (See <a href=\"topic.htm?path=pharmacotherapy-for-schizophrenia-side-effect-management\" class=\"medical medical_review\">&quot;Pharmacotherapy for schizophrenia: Side effect management&quot;</a> and <a href=\"topic.htm?path=tardive-dyskinesia-prevention-and-treatment\" class=\"medical medical_review\">&quot;Tardive dyskinesia: Prevention and treatment&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1430844239\"><span class=\"h1\">PSYCHOSOCIAL INTERVENTIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Psychosocial interventions for <span class=\"nowrap\">children/adolescents</span> with schizophrenia, in our clinical experience, are important adjuncts to treatment with antipsychotic medication. There have been few clinical trials of these interventions in youth; however, they are widely used clinically. Most were originally developed for adults; use in children requires customization to fit the patient&rsquo;s age, development, social setting, family, and risk factors. </p><p>The availability of psychosocial treatments for children with schizophrenia varies widely internationally. In the United States, they are more likely to be available in major metropolitan areas with large academic medical centers rather than in smaller cities or more rural areas. Psychosocial treatment programs may be more likely to incorporate principals and techniques from modalities we describe rather than to deliver a series of specific, discrete interventions.</p><p class=\"headingAnchor\" id=\"H2433463170\"><span class=\"h2\">Psychoeducation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Psychoeducation, best provided early in treatment and frequently reviewed, provides children and their <span class=\"nowrap\">parents/support</span> persons information about the illness, medications, and other interventions. It is highly useful to have family members integrated into the treatment team and educated in order to support the youth effectively and to enhance compliance. </p><p>There are no clinical trials evaluating the efficacy of psychoeducational interventions for <span class=\"nowrap\">children/adolescents</span> with schizophrenia and their families; however, in our clinical experience, developmentally appropriate psychoeducation is a critical component of care. Psychoeducation and family interventions for schizophrenia in adults are reviewed separately. (See <a href=\"topic.htm?path=psychosocial-interventions-for-schizophrenia#H13622397\" class=\"medical medical_review\">&quot;Psychosocial interventions for schizophrenia&quot;, section on 'Family-based Interventions'</a>.)</p><p class=\"headingAnchor\" id=\"H2164423916\"><span class=\"h2\">Individual and family therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Individual <span class=\"nowrap\">and/or</span> family therapy for <span class=\"nowrap\">children/adolescents</span> with schizophrenia varies in content but typically includes some combination of education, support, <span class=\"nowrap\">and/or</span> principles of problem solving therapy or cognitive-behavioral therapy (CBT). </p><p class=\"headingAnchor\" id=\"H3040845874\"><span class=\"h3\">Cognitive-behavioral therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CBT for <span class=\"nowrap\">children/adolescents</span> with schizophrenia (and in some cases family members) consists of:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cognitive approaches to address maladaptive and delusional beliefs.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Behavioral approaches, including social and vocational skills training. (See <a href=\"#H242461517\" class=\"local\">'Skills training'</a> below.)</p><p/><p>Treatment goals of CBT include reducing the intensity of delusions and hallucinations (and related distress), improving social functioning, and promoting the active engagement of children and families in treatment.</p><p>Clinical trials have found mixed evidence for the efficacy of CBT in <span class=\"nowrap\">children/adolescents</span> with schizophrenia<strong> </strong>[<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/35-37\" class=\"abstract_t\">35-37</a>]. As an example, a clinical trial randomly assigned 62 participants age 15 to 25 years with a first episode of psychosis to receive either CBT or a control condition [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/36\" class=\"abstract_t\">36</a>]. After 14 weeks, both groups had reductions in positive and negative symptoms, but no difference was seen between them in symptomatic or functional improvement. &#160;</p><p>CBT is used in adult schizophrenia to treat patients with symptoms resistant to antipsychotic medication. In contrast, in our clinical experience, all children with schizophrenia could benefit from CBT.</p><p>CBT for schizophrenia in adults is reviewed separately. (See <a href=\"topic.htm?path=psychosocial-interventions-for-schizophrenia#H633970811\" class=\"medical medical_review\">&quot;Psychosocial interventions for schizophrenia&quot;, section on 'Cognitive behavioral therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H242461517\"><span class=\"h2\">Skills training</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Social and vocational skills training are important components of psychosocial treatment for children. Surveys of patients consistently show positive functional outcomes as being equally, if not more, important to the patients than remission of symptoms [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/38\" class=\"abstract_t\">38</a>]. Social skills training is aimed at children with observed deficits such as problems with attention and working memory (eg, poor affect regulation). All adolescents should receive age-appropriate vocational skills training, which may also include help with placement and support during employment. &#160;</p><p>A clinical trial supports the use of vocational skills training in this population [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/38\" class=\"abstract_t\">38</a>]. Forty-one patients in the United Kingdom ages 15 to 25 years with schizophrenia were randomly assigned to receive individual placement and support or a control condition; patients assigned to the active intervention had higher rates of employment, earnings, and duration of employment compared with control group [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/39\" class=\"abstract_t\">39</a>]. &#160;</p><p>Social skills training for adults with schizophrenia is described separately. (See <a href=\"topic.htm?path=psychosocial-interventions-for-schizophrenia#H13622373\" class=\"medical medical_review\">&quot;Psychosocial interventions for schizophrenia&quot;, section on 'Social skills training'</a>.)</p><p class=\"headingAnchor\" id=\"H3899147054\"><span class=\"h2\">Therapeutic schools</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Therapeutic schools are used to educate children who struggle accessing the curriculum in a typical school setting due to mental illness or other emotional, behavioral, or psychological conditions. These schools vary but may offer academic assistance, counseling, behavior modification, individual and group therapy, as well as developmentally appropriate skill building to support these youth. Children or adolescents with schizophrenia who are treatment resistant or who have associated <span class=\"nowrap\">cognitive/emotional</span> challenges can benefit from therapeutic schools. </p><p>There are no clinical trials of the efficacy of therapeutic schools in youth with schizophrenia. </p><p class=\"headingAnchor\" id=\"H1134598262\"><span class=\"h2\">Cognitive enhancement/remediation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All youth with schizophrenia should receive cognitive enhancement therapy (or the similar cognitive remediation), if available, which consist of: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Computer-based exercises aimed at slowing deterioration in attention, memory, language, and executive functioning </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Social-cognitive group sessions for experiential learning and interpersonal interactions. </p><p/><p>Clinical trials suggest that cognitive enhancement therapy or remediation may be superior to other psychotherapies:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A two-year clinical trial randomly assigned 58 youth with early onset psychosis to receive either cognitive enhancement therapy or to enriched supportive therapy, finding that cognitive enhancement therapy led to superior results on social cognition, social adjustment, and symptomatology for cognition [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/40\" class=\"abstract_t\">40</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A three-month trial of cognitive remediation therapy in 40 adolescents with schizophrenia was found to be superior for cognitive flexibility (as evidenced by the Wisconsin Card Sort Test) in comparison to standard therapy [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/41\" class=\"abstract_t\">41</a>]. </p><p/><p>Although the availability of cognitive enhancement therapy, like other psychosocial interventions for youth with schizophrenia, is limited geographically, their availability is expanding to include online resources that can be done by the youth at home, which may provide benefit. Standardized definitions of cognitive <span class=\"nowrap\">remediation/enhancement</span> components have not been well defined; further study is needed.</p><p>Cognitive remediation for adults with schizophrenia is described separately. (See <a href=\"topic.htm?path=psychosocial-interventions-for-schizophrenia#H1343443\" class=\"medical medical_review\">&quot;Psychosocial interventions for schizophrenia&quot;, section on 'Cognitive remediation'</a>.)</p><p class=\"headingAnchor\" id=\"H3476926753\"><span class=\"h1\">PREVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Psychosocial and pharmacotherapeutic treatments have been tested for their ability to prevent or delay the onset of psychotic disorders in children at high (or &ldquo;ultra-high&rdquo;) clinical risk of developing a psychotic disorder. The criteria for these high risk states vary, ranging from prodromal symptoms (ie, disorganized or unusual thought content such as paranoia or suspiciousness, disorganized behavior) to the presence of psychotic symptoms below the threshold of a psychotic disorder.</p><p class=\"headingAnchor\" id=\"H4078913395\"><span class=\"h2\">Psychosocial interventions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A clinical trial randomly assigned 51 <span class=\"nowrap\">youth/young</span> adults (age range 14 to 30) at &ldquo;ultra-high&rdquo; risk for psychosis to receive either cognitive behavioral therapy or supportive therapy [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/42\" class=\"abstract_t\">42</a>]. No differences were found between groups at 6- or 12-month follow-up, though both groups showed improvement from baseline in attenuated positive symptoms, anxiety, and depression. </p><p>The findings are consistent with our clinical experience in suggesting that all youth with these high risk symptoms would benefit from supportive or cognitive-behavioral therapy as well as close clinical monitoring for conversion to psychosis. &#160;</p><p class=\"headingAnchor\" id=\"H1889369893\"><span class=\"h2\">Medications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Medications that have been tested, some in combination with psychosocial treatment, in youth at high risk for psychosis include:</p><p class=\"headingAnchor\" id=\"H2165429752\"><span class=\"h3\">Omega-3 fatty acids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical trials are mixed for the effect of long-chain omega-3 polyunsaturated fatty acids (PUFAs; 500 to 1000 mg twice daily) on the rate of transition to a psychotic disorder among <span class=\"nowrap\">youth/young</span> adults with subthreshold psychotic symptoms:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A trial randomly assigned 81 youth age 15 to 25 years with subthreshold psychosis to receive omega-3 PUFAs (1 gram twice daily) or placebo for 12 weeks [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/43\" class=\"abstract_t\">43</a>]. Both groups were offered a nine-session psychosocial intervention. After 12 months, subjects assigned to receive omega-3 PUFAs were less likely to transition to a psychotic disorder compared with the placebo group (4.9 versus 27.5 percent). Omega-3 PUFAs also led to reduced positive, negative and general symptoms, and improved functioning compared with placebo. The incidence of adverse effects did not differ between the treatment groups.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A trial randomly assigned 304 <span class=\"nowrap\">youth/young</span> adults (mean age 19 years) at ultrahigh risk for psychosis to receive dietary supplementation with long-chain omega-3 PUFAs (1.4 grams daily) in combination with cognitive behavioral case management or placebo plus the psychosocial intervention [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/44\" class=\"abstract_t\">44</a>]. After six months, there was no difference between groups in the rate of transition to psychosis (6.7 versus 5.1 percent).</p><p/><p>Potential side <span class=\"nowrap\">effects/adverse</span> effects of omega-3 fatty acids include bleeding and heartburn. The medications also have cardiovascular protective effects.</p><p class=\"headingAnchor\" id=\"H3889739079\"><span class=\"h3\">Antidepressants</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Two naturalistic studies, one prospective and the other retrospective, found that treatment with antidepressants but not with antipsychotic drugs was associated with reduced rates of progression to a psychotic disorder of adolescents with prodromal symptoms or at other states of high risk for schizophrenia [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/45,46\" class=\"abstract_t\">45,46</a>]. </p><p>As an example, the prospective observational study of 152 adolescents with prodromal symptoms included 20 subjects treated with selective serotonin reuptake inhibitor antidepressants and 28 treated with second-generation antipsychotics [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/46\" class=\"abstract_t\">46</a>]. Polypharmacy was common. The treatment groups did not differ in baseline symptom profiles, with the exception of disorganized thinking, which was more severe in second-generation antipsychotic-treated adolescents. Twelve of the 48 adolescents (25 percent) developed a psychotic disorder, with all converters having been prescribed second-generation antipsychotics. There were no conversions among antidepressant-treated adolescents. Eleven of the 12 converters were nonadherent, with nonadherence more common with second-generation antipsychotics compared with antidepressants (61 versus 20 percent).</p><p class=\"headingAnchor\" id=\"H2879642658\"><span class=\"h3\">Antipsychotics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The use of antipsychotic medication in prodromal or high risk patients with the aim of delaying or preventing conversion to psychosis is controversial and not supported by clinical trials [<a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/47,48\" class=\"abstract_t\">47,48</a>]. </p><p>As an example, a clinical trial randomly assigned 60 patients to receive <a href=\"topic.htm?path=olanzapine-pediatric-drug-information\" class=\"drug drug_pediatric\">olanzapine</a> (5 to 15 <span class=\"nowrap\">mg/day)</span> or placebo for one year, followed by a one-year period of no treatment. Over the course of the treatment year, in a near-significant finding, a smaller proportion of olanzapine patients compared with placebo patients experienced a conversion to psychosis (17 versus 40 percent). The conversion rate did not differ between groups during the subsequent year without treatment. The olanzapine patients experienced an average 9 kg weight gain compared with the placebo-treated patients. </p><p class=\"headingAnchor\" id=\"H944502899\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Schizophrenia in children and adolescents is a syndrome consisting of positive and negative symptoms of psychosis that impact development and cognitive functioning. The etiology of this syndrome is poorly understood, but early diagnosis and treatment are critical to limit the morbidity of the disorder.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Our approach to selecting treatments for schizophrenia in children and adolescents is described separately. (See <a href=\"topic.htm?path=approach-to-treating-schizophrenia-in-children-and-adolescents\" class=\"medical medical_review\">&quot;Approach to treating schizophrenia in children and adolescents&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antipsychotic medication is the cornerstone of treatment for schizophrenia in youth, augmented by psychosocial treatment. Multiple first- and second-generation antipsychotic medications have been found to reduce schizophrenia symptoms in children and adolescents. (See <a href=\"#H118040686\" class=\"local\">'Antipsychotic medication'</a> above and <a href=\"#H753168222\" class=\"local\">'Efficacy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Children and adolescents, compared with adults, are at higher risk of many of the side effects associated with antipsychotic use, including extrapyramidal side effects, withdrawal dyskinesias, elevated prolactin, weight gain, and metabolic abnormalities. Tardive dyskinesias are less common in youth compared with adult and older-adult populations than in youth. (See <a href=\"#H215092351\" class=\"local\">'Differences in youth'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neuroleptic malignant syndrome, agranulocytosis, myocarditis, cardiomyopathy, and severe allergic reactions are possible with antipsychotic medications and are a reason to terminate that medication immediately and provide appropriate medical care and support. (See <a href=\"#H1698346858\" class=\"local\">'Other adverse effects'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Psychosocial interventions are important adjuncts to antipsychotic treatment for <span class=\"nowrap\">children/adolescents</span> with schizophrenia, but have received little study in clinical trials. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Psychoeducation gives children and their <span class=\"nowrap\">parents/support</span> persons information about the illness, medications, and other interventions. (See <a href=\"#H2433463170\" class=\"local\">'Psychoeducation'</a> above.) </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Age-appropriate training in vocational skills and social skills aims to prevent deterioration in vocational and interpersonal functioning. (See <a href=\"#H242461517\" class=\"local\">'Skills training'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Cognitive remediation therapy consists of computer-based exercises aimed at slowing deterioration in attention, memory, language, and executive functioning. (See <a href=\"#H1134598262\" class=\"local\">'Cognitive enhancement/remediation'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Individual <span class=\"nowrap\">and/or</span> family therapy for <span class=\"nowrap\">children/adolescents</span> with schizophrenia varies in content but typically includes some combination of education, support, <span class=\"nowrap\">and/or</span> principles of problem solving therapy or cognitive-behavioral therapy. (See <a href=\"#H2164423916\" class=\"local\">'Individual and family therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Several medications aimed at delaying or reversing progression to a psychotic disorder among adolescents with prodromal symptoms or at states of high risk for schizophrenia have been tested in clinical trials. Trials of omega-3 fatty acids have shown mixed results. Selective serotonin reuptake inhibitor antidepressants have been shown to be helpful in a naturalistic study, but have not been tested in a clinical trial. Clinical trials have not found antipsychotics to be efficacious. (See <a href=\"#H3476926753\" class=\"local\">'Prevention'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/1\" class=\"nounderline abstract_t\">Childs B, Scriver CR. Age at onset and causes of disease. Perspect Biol Med 1986; 29:437.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/2\" class=\"nounderline abstract_t\">Rapoport JL, Gogtay N. Childhood onset schizophrenia: support for a progressive neurodevelopmental disorder. Int J Dev Neurosci 2011; 29:251.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/3\" class=\"nounderline abstract_t\">Nicolson R, Malaspina D, Giedd JN, et al. Obstetrical complications and childhood-onset schizophrenia. Am J Psychiatry 1999; 156:1650.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/4\" class=\"nounderline abstract_t\">Nicolson R, Giedd JN, Lenane M, et al. Clinical and neurobiological correlates of cytogenetic abnormalities in childhood-onset schizophrenia. Am J Psychiatry 1999; 156:1575.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/5\" class=\"nounderline abstract_t\">Findling RL, Cavu&#351; I, Pappadopulos E, et al. Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study. J Child Adolesc Psychopharmacol 2013; 23:531.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/6\" class=\"nounderline abstract_t\">Kryzhanovskaya L, Schulz C, McDougle CJ, et al. A double-blind, placebo-controlled study of olanzapine in adolescents with schizophrenia. Neuropsychopharmacology 2005; 30:S258.</a></li><li class=\"breakAll\">Robb AS, Findling RL, Nyilas M, et al. Efficacy of aripiprazole in the treatment of adolescents with schizophrenia. In: 2007 Annual Meeting New Research Program and Abstracts, American Psychiatric Association, Arlington 2007. p.319.</li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/8\" class=\"nounderline abstract_t\">Findling RL, Robb A, Nyilas M, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008; 165:1432.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/9\" class=\"nounderline abstract_t\">Correll CU, Kohegyi E, Zhao C, et al. Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study. J Am Acad Child Adolesc Psychiatry 2017; 56:784.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/10\" class=\"nounderline abstract_t\">Findling RL, McKenna K, Earley WR, et al. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 2012; 22:327.</a></li><li class=\"breakAll\">Haas M, Unis AS, Copenhaver M, et al. Efficacy and safety of risperidone in adolescents with schizophrenia. In: 2007 Annual Meeting New Research Program and Abstracts, American Psychiatric Association, Arlington 2007. p.221.</li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/12\" class=\"nounderline abstract_t\">Goldman R, Loebel A, Cucchiaro J, et al. Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study. J Child Adolesc Psychopharmacol 2017; 27:516.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/13\" class=\"nounderline abstract_t\">Savitz AJ, Lane R, Nuamah I, et al. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study. J Am Acad Child Adolesc Psychiatry 2015; 54:126.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/14\" class=\"nounderline abstract_t\">Singh J, Robb A, Vijapurkar U, et al. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry 2011; 70:1179.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/15\" class=\"nounderline abstract_t\">Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996; 53:1090.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/16\" class=\"nounderline abstract_t\">Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006; 63:721.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/17\" class=\"nounderline abstract_t\">Werry JS, Weiss G, Douglas V, Martin J. Studies on the hyperactive child. 3. The effect of chlorpromazine upon behavior and learning ability. J Am Acad Child Psychiatry 1966; 5:292.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/18\" class=\"nounderline abstract_t\">Pool D, Bloom W, Mielke DH, et al. A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr Ther Res Clin Exp 1976; 19:99.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/19\" class=\"nounderline abstract_t\">Spencer EK, Kafantaris V, Padron-Gayol MV, et al. Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacol Bull 1992; 28:183.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/20\" class=\"nounderline abstract_t\">Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine versus &quot;high-dose&quot; olanzapine in refractory early-onset schizophrenia: an open-label extension study. J Child Adolesc Psychopharmacol 2008; 18:307.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/21\" class=\"nounderline abstract_t\">Lytle S, McVoy M, Sajatovic M. Long-Acting Injectable Antipsychotics in Children and Adolescents. J Child Adolesc Psychopharmacol 2017; 27:2.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/22\" class=\"nounderline abstract_t\">Schneider C, Corrigall R, Hayes D, et al. Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia. Eur Psychiatry 2014; 29:1.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/23\" class=\"nounderline abstract_t\">Gerbino-Rosen G, Roofeh D, Tompkins DA, et al. Hematological adverse events in clozapine-treated children and adolescents. J Am Acad Child Adolesc Psychiatry 2005; 44:1024.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/24\" class=\"nounderline abstract_t\">Alvir JM, Lieberman JA. Agranulocytosis: incidence and risk factors. J Clin Psychiatry 1994; 55 Suppl B:137.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/25\" class=\"nounderline abstract_t\">Sporn A, Gogtay N, Ortiz-Aguayo R, et al. Clozapine-induced neutropenia in children: management with lithium carbonate. J Child Adolesc Psychopharmacol 2003; 13:401.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/26\" class=\"nounderline abstract_t\">Findling RL, Frazier JA, Gerbino-Rosen G, et al. Is there a role for clozapine in the treatment of children and adolescents? J Am Acad Child Adolesc Psychiatry 2007; 46:423.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/27\" class=\"nounderline abstract_t\">Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2011; 21:517.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/28\" class=\"nounderline abstract_t\">Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47:9.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/29\" class=\"nounderline abstract_t\">Correll CU, Penzner JB, Parikh UH, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am 2006; 15:177.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/30\" class=\"nounderline abstract_t\">Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006; 45:771.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/31\" class=\"nounderline abstract_t\">Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry 2007; 46:687.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/32\" class=\"nounderline abstract_t\">Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302:1765.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/33\" class=\"nounderline abstract_t\">Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161:414.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/34\" class=\"nounderline abstract_t\">Kranzler HN, Cohen SD. Psychopharmacologic treatment of psychosis in children and adolescents: efficacy and management. Child Adolesc Psychiatr Clin N Am 2013; 22:727.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/35\" class=\"nounderline abstract_t\">Gleeson JF, Cotton SM, Alvarez-Jimenez M, et al. A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients. J Clin Psychiatry 2009; 70:477.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/36\" class=\"nounderline abstract_t\">Jackson HJ, McGorry PD, Killackey E, et al. Acute-phase and 1-year follow-up results of a randomized controlled trial of CBT versus Befriending for first-episode psychosis: the ACE project. Psychol Med 2008; 38:725.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/37\" class=\"nounderline abstract_t\">Haddock G, Lewis S, Bentall R, et al. Influence of age on outcome of psychological treatments in first-episode psychosis. Br J Psychiatry 2006; 188:250.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/38\" class=\"nounderline abstract_t\">Killackey E, Alvarez-Jimenez M, Allott K, et al. Community rehabilitation and psychosocial interventions for psychotic disorders in youth. Child Adolesc Psychiatr Clin N Am 2013; 22:745.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/39\" class=\"nounderline abstract_t\">Killackey E, Jackson HJ, McGorry PD. Vocational intervention in first-episode psychosis: individual placement and support v. treatment as usual. Br J Psychiatry 2008; 193:114.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/40\" class=\"nounderline abstract_t\">Eack SM, Greenwald DP, Hogarty SS, et al. Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial. Psychiatr Serv 2009; 60:1468.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/41\" class=\"nounderline abstract_t\">Wykes T, Newton E, Landau S, et al. Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: an exploratory randomized controlled trial. Schizophr Res 2007; 94:221.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/42\" class=\"nounderline abstract_t\">Addington J, Epstein I, Liu L, et al. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res 2011; 125:54.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/43\" class=\"nounderline abstract_t\">Amminger GP, Sch&auml;fer MR, Papageorgiou K, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67:146.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/44\" class=\"nounderline abstract_t\">McGorry PD, Nelson B, Markulev C, et al. Effect of &omega;-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial. JAMA Psychiatry 2017; 74:19.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/45\" class=\"nounderline abstract_t\">Fusar-Poli P, Frascarelli M, Valmaggia L, et al. Antidepressant, antipsychotic and psychological interventions in subjects at high clinical risk for psychosis: OASIS 6-year naturalistic study. Psychol Med 2015; 45:1327.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/46\" class=\"nounderline abstract_t\">Cornblatt BA, Lencz T, Smith CW, et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry 2007; 68:546.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/47\" class=\"nounderline abstract_t\">McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59:921.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacotherapy-and-psychosocial-interventions-for-schizophrenia-in-children-and-adolescents/abstract/48\" class=\"nounderline abstract_t\">McGlashan TH, Zipursky RB, Perkins D, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163:790.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 112632 Version 1.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H944502899\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H3346353019\" id=\"outline-link-H3346353019\">INTRODUCTION</a></li><li><a href=\"#H1604998047\" id=\"outline-link-H1604998047\">APPROACH TO TREATMENT</a></li><li><a href=\"#H118040686\" id=\"outline-link-H118040686\">ANTIPSYCHOTIC MEDICATION</a><ul><li><a href=\"#H753168222\" id=\"outline-link-H753168222\">Efficacy</a><ul><li><a href=\"#H3756837637\" id=\"outline-link-H3756837637\">- Clozapine</a></li><li><a href=\"#H477881056\" id=\"outline-link-H477881056\">- Long-acting injectable formulations</a></li></ul></li><li><a href=\"#H2178695808\" id=\"outline-link-H2178695808\">Side effects</a><ul><li><a href=\"#H750318012\" id=\"outline-link-H750318012\">- First-generation antipsychotics</a></li><li><a href=\"#H1022592751\" id=\"outline-link-H1022592751\">- Second-generation antipsychotics</a><ul><li><a href=\"#H1502854672\" id=\"outline-link-H1502854672\">Clozapine</a></li></ul></li><li><a href=\"#H215092351\" id=\"outline-link-H215092351\">- Differences in youth</a></li><li><a href=\"#H1698346858\" id=\"outline-link-H1698346858\">- Other adverse effects</a></li><li><a href=\"#H3172361488\" id=\"outline-link-H3172361488\">- Management</a></li></ul></li></ul></li><li><a href=\"#H1430844239\" id=\"outline-link-H1430844239\">PSYCHOSOCIAL INTERVENTIONS</a><ul><li><a href=\"#H2433463170\" id=\"outline-link-H2433463170\">Psychoeducation</a></li><li><a href=\"#H2164423916\" id=\"outline-link-H2164423916\">Individual and family therapy</a><ul><li><a href=\"#H3040845874\" id=\"outline-link-H3040845874\">- Cognitive-behavioral therapy</a></li></ul></li><li><a href=\"#H242461517\" id=\"outline-link-H242461517\">Skills training</a></li><li><a href=\"#H3899147054\" id=\"outline-link-H3899147054\">Therapeutic schools</a></li><li><a href=\"#H1134598262\" id=\"outline-link-H1134598262\">Cognitive enhancement/remediation</a></li></ul></li><li><a href=\"#H3476926753\" id=\"outline-link-H3476926753\">PREVENTION</a><ul><li><a href=\"#H4078913395\" id=\"outline-link-H4078913395\">Psychosocial interventions</a></li><li><a href=\"#H1889369893\" id=\"outline-link-H1889369893\">Medications</a><ul><li><a href=\"#H2165429752\" id=\"outline-link-H2165429752\">- Omega-3 fatty acids</a></li><li><a href=\"#H3889739079\" id=\"outline-link-H3889739079\">- Antidepressants</a></li><li><a href=\"#H2879642658\" id=\"outline-link-H2879642658\">- Antipsychotics</a></li></ul></li></ul></li><li><a href=\"#H944502899\" id=\"outline-link-H944502899\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PSYCH/112632|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PSYCH/116251\" class=\"graphic graphic_table\">- Antipsychotic dosing in children and adolescents schizophrenia</a></li><li><a href=\"image.htm?imageKey=PSYCH/59201\" class=\"graphic graphic_table\">- Dose and admin of LAI antipsychotic for schizophrenia</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-treating-schizophrenia-in-children-and-adolescents\" class=\"medical medical_review\">Approach to treating schizophrenia in children and adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-and-management-of-treatment-resistant-schizophrenia\" class=\"medical medical_review\">Evaluation and management of treatment-resistant schizophrenia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=first-generation-antipsychotic-medications-pharmacology-administration-and-comparative-side-effects\" class=\"medical medical_review\">First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=guidelines-for-prescribing-clozapine-in-schizophrenia\" class=\"medical medical_review\">Guidelines for prescribing clozapine in schizophrenia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacotherapy-for-schizophrenia-acute-and-maintenance-phase-treatment\" class=\"medical medical_review\">Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacotherapy-for-schizophrenia-long-acting-injectable-antipsychotic-drugs\" class=\"medical medical_review\">Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacotherapy-for-schizophrenia-side-effect-management\" class=\"medical medical_review\">Pharmacotherapy for schizophrenia: Side effect management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=psychosocial-interventions-for-schizophrenia\" class=\"medical medical_review\">Psychosocial interventions for schizophrenia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=schizophrenia-in-adults-clinical-manifestations-course-assessment-and-diagnosis\" class=\"medical medical_review\">Schizophrenia in adults: Clinical manifestations, course, assessment, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=schizophrenia-in-adults-epidemiology-and-pathogenesis\" class=\"medical medical_review\">Schizophrenia in adults: Epidemiology and pathogenesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=schizophrenia-in-children-and-adolescents-epidemiology-pathogenesis-clinical-manifestations-course-assessment-and-diagnosis\" class=\"medical medical_review\">Schizophrenia in children and adolescents: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=second-generation-antipsychotic-medications-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">Second-generation antipsychotic medications: Pharmacology, administration, and side effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tardive-dyskinesia-clinical-features-and-diagnosis\" class=\"medical medical_review\">Tardive dyskinesia: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tardive-dyskinesia-etiology-and-epidemiology\" class=\"medical medical_review\">Tardive dyskinesia: Etiology and epidemiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tardive-dyskinesia-prevention-and-treatment\" class=\"medical medical_review\">Tardive dyskinesia: Prevention and treatment</a></li></ul></div></div>","javascript":null}